Full Text
Amnog Early Benefit Assessment (EBA) in Germany - A Specific Challenge for Antidiabetics

Abstract

Authors

H Bleß J Mathes W Kotowa C Lübker

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×